News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
119 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39673)
2015 (44433)
2016 (38330)
2017 (37191)
2018 (39124)
2019 (51338)
2020 (57666)
2021 (58724)
2022 (53928)
2023 (42568)
2024 (38486)
2025 (17535)
Month
January (2488)
February (2603)
March (3229)
April (2950)
May (3962)
June (3500)
July (2854)
August (3142)
September (3205)
October (3540)
November (3386)
December (2332)
Day
2 (186)
3 (175)
4 (147)
5 (166)
6 (119)
9 (121)
10 (183)
11 (172)
12 (142)
13 (112)
14 (38)
15 (1)
16 (171)
17 (154)
18 (148)
19 (149)
20 (92)
21 (2)
23 (153)
24 (148)
25 (216)
26 (204)
27 (119)
28 (2)
29 (9)
30 (193)
31 (218)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Month
January
February
March
April
May
June
July
August
September
October
November
December
Day
2
3
4
5
6
9
10
11
12
13
14
15
16
17
18
19
20
21
23
24
25
26
27
28
29
30
31
Policy
Merck Drops After Withdrawing European App for Wonder Drug Keytruda
Late on Friday, Merck announced that it had pulled its application for Keytruda in combination with pemetrexed and carboplatin as a first-line treatment for metastatic nonsquamous NSCLC from the EMA.
October 27, 2017
·
2 min read
·
Mark Terry
BioCapital
Why This Pharma Surged After Trump’s Opioid Declaration
Opiant Pharmaceuticals spiked 46 percent Thursday when President Donald Trump declared a crackdown on opioid abuse.
October 27, 2017
·
1 min read
Policy
Billionaire Insys Founder Charged With Bribing Doctors to Prescribe Opioid Painkillers
Once again Insys has been rocked by an indictment.
October 27, 2017
·
3 min read
·
Alex Keown
Policy
Johnson & Johnson Lawyers Vehemently Denies Tampering Allegations in Hip Case
Last week a federal judge asked prosecutors and the FBI to look into possible witness tampering.
October 27, 2017
·
1 min read
Genetown
Hackers are Able to Exploit Boston Scientific’s Zoom Latitude Device, Says Feds
The Zoom Latitude programmer is made by a Boston Scientific division headquartered in Minnesota.
October 27, 2017
·
1 min read
Business
Xtant Medical to Announce Third Quarter 2017 Results on Wednesday, November 8th
An accompanying conference call will be conducted by the CEO and CFO to review the results.
October 27, 2017
·
4 min read
FDA
Butterfly Network’s First Ultrasound-on-a-Chip Receives Broadest FDA 510(k) Clearance
The clearance covers 13 clinical applications, the broadest ever for a single ultrasound transducer.
October 27, 2017
·
4 min read
Business
ICON and the International Consortium for Health Outcomes Measurement Unveil the World’s First Global Patient Outcomes Benchmarking Platform
ICON, and the International Consortium for Health Outcomes Measurement (ICHOM) shared the findings of a global patient outcomes benchmarking platform at this week’s ICHOM’s annual conference in Washington DC.
October 27, 2017
·
6 min read
Medovex Corporation Comments on President Trump Declaring the Opioid Crisis a National Public Health Emergency
National Center for Health Statistics estimate drug overdoses due to opioid use increased 21% in 2016; 64,070 Americans died as a result of opioid use in the last year.
October 27, 2017
·
4 min read
Drug Development
ORIC Pharma Announces First Subject Dosed in Phase I Clinical Study of Novel GR Antagonist with Planned Development for Oncology
ORIC Pharma announced today that the first subject in a Phase Ia clinical study has been dosed with ORIC-101, a potent small molecule inhibitor of the glucocorticoid receptor.
October 27, 2017
·
2 min read
Previous
2 of 12
Next